A longstanding and still-increasing threat to the effective treatment of infectious diseases is resistance to antimicrobial countermeasures. Potentially, the targeting of host proteins and pathways essential for the detrimental effects of pathogens offers an approach that may discover broad-spectrum anti-pathogen countermeasures and circumvent the effects of pathogen mutations leading to resistance. Here we report implementation of a strategy for discovering broad-spectrum host-oriented therapies against multiple pathogenic agents by multiplex screening of drugs for protection against the detrimental effects of multiple pathogens, identification of host cell pathways inhibited by the drug, and screening for effects of the agent on other pathogens exploiting the same pathway. We show that a clinically used antimalarial drug, Amodiaquine, discovered by this strategy, protects host cells against infection by multiple toxins and viruses by inhibiting host cathepsin B. Our results reveal the practicality of discovering broadly acting anti-pathogen countermeasures that target host proteins exploited by pathogens.
Whereas medical treatments generally target specific cellular functions of patients to cure or mitigate the effects of diseases, the strategy underlying treatment of infectious disease treatment is to target the infecting pathogen1. Inevitably, and not surprisingly, the targeting of pathogens has led to the emergence and spread among pathogens of mutational resistance to countermeasures. Such resistance, together with a desire to expand the utility of countermeasures by increasing their range of therapeutic efficacy, has in recent years sparked interest in agents aimed at host functions that pathogens exploit to enter or be released from host cells1. Not infrequently, multiple pathogens or toxins that affect hosts by different mechanisms use the same host pathways2, raising the prospect that multiplex strategies that concurrently or sequentially screen for host functions exploited by multiple pathogenic agents may lead to the discovery of broadly active and host-oriented infectious disease countermeasures.
Here we report the discovery, using a cell-based multiplex approach to screen a library of FDA-approved drugs for the ability to interfere with disparately acting pathogens. We report here, that a compound used clinically as an antimalarial agent, inhibits both the detrimental effects of multiple bacterial toxins and the entry of Ebola and other viruses into host cells. We further show that the broad antipathogenic actions of Amodiaquine result from its ability to interfere with the functioning of the host protein, cathepsin B.
Screening of FDA approved drugs for inhibitors of toxin - induced cell death
In a systematic effort to identify candidates for repurposing drugs as broad-spectrum, host-oriented, anti-toxin countermeasures, we screened members of the Johns Hopkins Clinical Compound Library (JHCCL)3 of 1,581 agents previously approved as drugs by the US Food and Drug Administration for the ability to reduce lethality of RAW264.7 and C32 cells treated either with Bacillus anthracis lethal toxin or diphtheria toxin (Fig. 1a). These toxins were chosen because the mechanisms underlying their pathogenicity are well understood and are disparate to each other.
Between 50 and 70 percent of cells used for these assays normally undergo cell death, as determined by MTT assay, within 6 and 24 hours of exposure to anthrax lethal toxin and diphtheria toxin respectively, under the experimental conditions employed. A “hit” in our screen was defined as an event where cells exposed to a compound at a concentration of 16 μM increased cell survival by at least 16 standard deviations (~1% hit rate) above the survival of control cells treated with either toxin, but is not cytotoxic to cells in the absence of toxins. Events defined as “multiplex hits” interfered with cell killing by both of the toxins (Fig. 1b). Five multiplex hits were identified and were tested further.
Anthrax toxin and diphtheria toxin enter the cytoplasm from acidified endosomes4. Whereas diphtheria toxin is an ADP ribosyl transferase, anthrax toxin is a protease that cleaves host MAPKK (Fig. 1c). To identify agents that inactivate host proteins exploited by toxins, we focused on hits that inhibit the mechanistically differently acting anthrax and diphtheria toxins. In order to elucidate host-targets inhibited by these drugs, we used only anthrax toxin, as the host cellular pathway that delivers the anthrax toxin into the cytoplasm is one of the best understood pathways5 (and Fig. 1c). Anthrax lethal toxin is an exotoxin protein complex consisting of protective antigen (PA) and lethal factor (LF), which act collectively to damage the host cell6. PA is an 83 kDa cellular receptor-binding protein (PA83), and the combination of PA with LF is cytotoxic6. LF is a 91 kDa zinc metalloprotease that cleaves the N-terminal substrate docking site of the mitogen-activated protein kinase kinases (MAP2K), preventing the passage of signals in the ERK1/2, p38, and c-Jun N-terminal kinase pathways7. Intoxication of a cell begins when PA83 binds to host cellular receptors, capillary morphogenesis protein 2 (CMG2), tumor endothelial marker 8 (TEM8), or integrin beta 1 (ITGB1)2,8,9. Once bound, host furin cleaves a 20 kDa fragment from the N-terminus of PA83, thus activating the 63 kDa protein, PA6310. Following activation, PA63 forms a heptamer and binds LF11. The toxin undergoes clathrin-mediated endocytosis and a decrease in endosomal pH induces the formation of an endosomal membrane PA channel, by which LF translocates into the cytosol12 before PA pores are transported to lysosomes for rapid degradation8,13,14. PA has been shown to induce the process of autophagy, whereby autophagosomes encapsulate endosomes and facilitate the delivery of LF into the cytoplasm15. A lysosomal protein, cathepsin B, is necessary for the autophagic flux, whereby LF is delivered from the intralumenal vesicles of the autophagosome-encapsulated multivesicular late endosomes into the cytoplasm through a back fusion process14,16,17.
We observed that out of five compounds that inhibited anthrax and diphtheria toxins, two compounds were structurally related 4-amino-quinolines, Chloroquine and Amodiaquine. Two anti-malarial drugs, Chloroquine (CQ) and Amodiaquine (AQ), were observed to completely protect host cells against anthrax toxin killing in 6-hours toxin killing assay (Fig. 2a). However, our assay showed that unlike AQ, CQ only has a moderate ability to protect cells against LF-PA mediated 24-hours killing (Fig. 2b). Interestingly, none of the other quinoline-containing antimalarial compounds, Cinchonine, Primaquine, and Quinidine, from JHCCL were active (Supplementary Fig. 1a–c).
Amodiaquine and its metabolite are potent inhibitors of LF-PA induced death in vitro and in vivo
After oral administration, AQ is rapidly absorbed and undergoes fast and extensive metabolisation by hepatocytes’ cytochrome p450 enzyme to the AQ metabolite, Desethyl-Amodiaquine (DEAQ), the main active metabolite of AQ16. We tested the ability of DEAQ to reduce anthrax toxin mediated cellular killing, and we observed that just like AQ, DEAQ was able to reduce toxin-mediated cytotoxicity with an EC50 of 5 μM (Fig. 2c). Since AQ and its metabolite, DEAQ, protected host cells against anthrax toxin killing, we evaluated the efficacy of AQ as a therapeutic agent during anthrax toxin intoxication in Sprague-Dawley rats. Animals were injected intravenously with a lethal dose of anthrax toxin (LD100) and were intravenously co-injected with AQ at 1.5, 3.0, or 6.0 mg/kg. The AQ doses were selected based on the FDA approved AQ dose of 10 mg/kg18. Animals that received a lethal dose of anthrax toxin without AQ all died within 90 minutes post intoxication (Fig. 2d). While the administration of AQ at 1.5 mg/kg saved 40% of the rats, all of the animals in that group displayed classical signs of having undergone a toxin challenge, such as ataxia, lethargy, hyperpnea, and tachypnea. Rats that were challenged with anthrax toxin and treated with AQ at 3.0 and 6.0 mg/kg all survived without displaying toxin-associated symptoms (Fig. 2d).
Amodiaquine Inhibits Cytosolic Entry of LF
In order to identify the step at which AQ inhibits LF-PA-mediated lethality, we assessed the processes that mediate the cellular entry of this toxin and toxin-induced pyroptosis in the presence and in the absence of this drug. Caspase-1 activation, which occurs late in LF-PA intoxication, was monitored using a fluorescent probe, FLICA. This probe specifically binds to active caspase-1. While we observed high levels of caspase-1 activity upon LF-PA treatment in the absence of AQ, active caspase-1 was not detected in AQ-treated cells that were challenged with anthrax toxin (Fig. 3a). This result shows that AQ inhibits cytotoxicity upstream of caspase-1 activation.
Activation of caspase-1 by LF is a late step in pyroptosis and depends on LF catalytic activity19. To determine whether AQ blocks proteolysis of cellular MAPKKs by LF, we assessed the cleavage of MEK2 by immunobloting. While MEK2 was cleaved in LF-PA treated RAW264.7 cells, treatment with AQ completely prevented this effect (Fig. 3b). These results show that AQ inhibits either cytotoxicity upstream of MAPKK cleavage or blocks LF directly.
In order to test whether AQ inhibits the enzymatic activity of LF, we used a Fluorescence Resonance Energy Transfer (FRET) based assay, in which an MEK2 peptide containing a cleavage site for LF with a fluorogenic DABCYL group at the N-terminus and FITC quenching group at the C-terminus was used as LF substrate for in vitro assays. After cleavage by LF, the fluorescence emitted by the DABCYL increased (Fig. 3c). We tested the ability of AQ to inhibit the proteolytic activity of LF at 16 μM using FRET. In the presence of a known small molecule inhibitor of LF, surfen hydrate20, no emission at 523 nm was seen (Fig. 3c). In the absence of any chemical inhibitor, LF cleaved MAPKK peptide, and the fluorescence emission was observed (Fig. 3c). A similar emission at 523 nm was observed when LF was able to cleave MAPKK peptide in the presence of AQ, which shows that AQ does not block the proteolytic activity of LF at 16 μM.
AQ-treated cells were found to be less sensitive to treatment with PA + FP59 (Fig. 3d,e). FP59 is a hybrid toxin, which contains the PA binding site of LF as well as a toxin domain derived from P. aeruginosa exotoxin A21, that has been widely used as an LF surrogate, and kills cells by a different mechanism2. This result, along with the caspase-1 and MEK2 data, strongly suggest that AQ interferes with PA mediated toxin entry.
Amodiaquine binds to and inhibits host cathepsin B
In order for LF to reach the cytosol, PA83 must bind to host cell receptors, be cleaved by furin into PA63, heptamerize into a pre-pore form, bind LF, and proceed to low-pH endosomes where PA-heptamers undergo an acid-dependent conformational change from pre-pore to pore22. Host-cell binding of PA and its proteolytic cleavage were monitored by immunoblot in the presence and in the absence of AQ. We observed that AQ did not block binding of PA83 to cells or block proteolytic processing of PA to generate PA63 (Fig. 4a). The inability of AQ to block the activity of host furin cleavage of PA83 is consistent with our observation that AQ equally reduces sensitivity of host cells to both PA83 + LF and PA63 + LF treatments (Supplementary Fig. 2). These results indicate that AQ blocks intoxication at a step downstream of PA binding and assembly on the host-cell surface.
CQ was previously shown to prevent endosomal acidification23. Since AQ is structurally similar to CQ, we tested whether AQ neutralizes anthrax toxin induced endosomal acidification. We used Lysosensor Green DND-189 to probe acidic organelles in the cells. Lysosensor is a green fluorescent dye used for tracking acidic organelles in the cell. Neutralization of these compartments can be visualized as a loss in punctate-fluorescent structures. In the absence of AQ, PA-treated cells displayed Lysosensor fluorescence, and AQ markedly decreased cell-associated Lysosensor fluorescence (Fig. 4b). These results predict that AQ may block the ability of PA to either access acidified endosomes or to form PA pores. It is known that the pore formation of PA, which results from exposure to acidic pH within endosomes, is resistant to dissociation by SDS and runs as an oligomer on SDS-PAGE22. Surprisingly, treatment of cells with AQ resulted in higher, rather than lower, abundance of SDS-resistant PA-oligomers compared to cells treated with PA only (Fig. 4c).
A similar observation was reported by Ha et al.14, who showed that an inhibition of host lysosomal cathepsin B by an unrelated small molecule CA-074, resulted in (i) elevated accumulation of PA pores in late endosomes, (ii) the inability of LF to be released from the late endosomes into the cytoplasm, and (iii) results in reduction of cellular sensitivity to LF-PA. Upon formation of the SDS-resistant PA63 pore in acidic endosomes, PA pores are then transported to lysosomes for rapid degradation24. Ha et al. showed that cathepsin B mediates the fusion of lysosomes with endosomes, and that this fusion is necessary for the release of LF from the endosomes into the cytoplasm14. In order to gain further insight into the mechanism of AQ-mediated protection of cells against anthrax toxin killing, we tested whether AQ inhibits cathepsin B protease activity of purified human cathepsin B using a FRET assay. We observed that both AQ and DEAQ directly inhibit cathepsin B activity in a dose dependent manner without drug pre-incubations, at drug concentrations used in cellular experiments (Fig. 4d). We tested whether AQ inhibits cathepsin B in RAW264.7 cells. We observed that cells pre-treated with AQ or with DEAQ for 1 hour lost cathepsin B enzymatic activity in a dose dependent manner (Supplementary Fig. 3a). In addition, we tested the ability to AQ to inhibit cathepsin B activity in a protein lysate from cells that were not exposed to drugs prior to the lysis, and we observed that AQ and DEAQ inhibited cathepsin B activity (Supplementary Fig. 3b). We determined that the addition of drugs to cathepsin B reactions did not change the pH (pH 5.8) of the reaction buffer. In all of the cathepsin B experiments we observed that CQ and its metabolite, Desethyl-Chloroquine (DECQ), were weaker inhibitors of cathepsin B activity (Fig. 4d and Figure S3), which corresponds to the phenotypic data seen in Fig. 2.
The interaction between AQ and cathepsin B was probed using saturation transfer difference NMR spectroscopy (STD). This technique is a powerful label-free ligand-observed tool to study molecular interactions in solution25,26. STD relies on the transfer of selective saturation (excitation) of the protein’s atoms to atoms located in the bound ligand. Two 1D 1H-NMR spectra are acquired—one in which the protein’s signals are selectively saturated (“on” resonance, Isat), and another in which no signals are saturated (“off” resonance, I0). Ligand binding is evident by the difference spectrum (I0 − Isat), as only when binding occurs are the signals of the ligand affected. Figure 4e shows the 1H-NMR spectrum of 2 mM AQ in the presence of 20 μM cathepsin B (ligand:protein molar ratio of 100:1), and its corresponding STD difference spectrum. The presence of AQ signals in the difference spectrum clearly indicates that it is binding to the enzyme. An inspection of the atom-specific effects provides insight into the mode of binding. Atoms in the quinoline backbone display the largest reduction in their intensities, suggesting that they are in close proximity to cathepsin B (Fig. 4f, atoms H4 and H5 exhibit STD effects of 100 and 97%, respectively). In contrast, the H9 and H10 methylene protons are modestly affected, suggesting that in the complex they are located distal to hydrogen atoms in the protein. Interestingly, several atoms in the phenol ring display substantial STD effects suggesting that they are near the protein. This is consistent with the lower biological activities of AQ analogs that remove the phenol ring (Fig. 2 and Supplementary Fig. 1). The importance of the AQ quinoline ring revealed by STD is also compatible with the crystal structure of cathepsin B bound to nitroxoline, as this small molecule contains a quinoline moiety that interacts extensively with the enzyme27.
Amodiaquine inhibits pathogenicity of Ebola virus
Upon observing that AQ protects cells from anthrax and diphtheria toxins, we hypothesized that AQ and DEAQ might also be able to inhibit the entry of Ebola virus. Ebola virus, among other viruses, requires low endosomal pH28 as well as host cathepsin B function29 for membrane fusion and infection of host cells. In fact, AQ and CQ have recently been reported to inhibit Ebola virus pathogenicity in cells28,29. We re-tested AQ and CQ’s ability to inhibit Ebola virus abundance in infected HeLa cells by visualizing infected cells using immune-staining, and in addition we tested the ability of their metabolites, DEAQ and DECQ, to inhibit Eboa virus propagation in cultured cells in vitro. To test AQ-mediated inhibition of viral propagation, we compared infection by Ebola virus (Kikwit) at MOI of 0.5 with and without drugs for 48 hours. To detect infected cells, immuno-staining was completed with anti-Ebola-glycoprotein antibodies. AQ and DEAQ effectively inhibited propagation of Ebola virus in HeLa cells with EC50’s in the low μM range (Table 1): the EC50’s of AQ and DEAQ were 3.8 and 3.6 μM respectively. The EC50’s of CQ and DECQ in HeLa were 4.8 and 7.3 μM respectively. This data shows that DEAQ is more efficacious in inhibiting Ebola propagation compared to DECQ. Similar results were obtained by testing AQ, CQ, DEAQ, and DECQ for their ability to inhibit Ebola virus in primary human cell line, HFF-1 (Supplementary Table 1). This result confirms that anti-viral effect of AQ is not related to its effects on the host cell cycle or cellular proliferation.
The life cycle of Ebola virus in cultured host cells is 20–24 hours. To more clearly evaluate effects of AQ and DEAQ on a single viral life cycle, we compared the inhibitory effects of these drugs after 24 and 48 hours of Ebola virus infection in cells. We observed that AQ and DEAQ are at least two times more potent after 24 h of infection (EC50’s 2 μM), compared to 48 h, during which time the secondary round of infection occurs and possibly slightly decreases the antiviral efficacies of AQ and DEAQ (EC50’s 4 μM) (Table 2).
Amodiaquine inhibits pathogenicity of other Category A, B, and C pathogenic agents that enter into host cytoplasm from acidified endosomes
In addition to anthrax toxin15, diphtheria toxin30, and Ebola virus29,31, other pathogenic agents SARS coronavirus31, Venezuelan equine encephalitis virus (VEEV)32, Rabies virus33, Junin virus34, Chikungunya virus35, and Clostridium difficile toxin B36 enter the cytoplasm from endosomes and all require the acidification of endosomes. We demonstrated that all of those pathogenic agents are inhibited by AQ in their respective in vitro cellular assays (Table 3 and Supplementary Fig. 4a). We also tested the ability of DEAQ to inhibit pathogenicity of Junin and Chikungunya viruses, and observed that DEAQ inhibits those two viruses with EC50’s similar to those of AQ (Supplementary Table 2).
Other pathogenic agents, including cholera toxin37, Pseudomonas aeruginosa exotoxin A38, Poliovirus 318, and Herpes simplex virus 139 are transported in a retrograde fashion to the endoplasmic reticulum (ER) and retrotranslocated into the cytoplasm by the host ER-associated degradation pathway37,38. We observed that cytotoxicity mediated by those pathogens was not blocked by AQ (Table 3 and Supplementary Fig. 4b,c). In addition, the inability of AQ to inhibit cholera and Pseudomonas toxins, which are both ADP-rybosyltransferases, suggests that AQ’s adverse effect on diphtheria toxin (Fig. 1), which is also ADP-rybosyltransferase, occurs by inhibition of host cathepsin B only.
Another group of pathogens enter the cytoplasm by ways that do not rely on the acidification of endosomes, and include Human Cytomegalovirus40 and Respiratory syncytial virus41. We determined that AQ did not reduce the pathogenicity of those viruses (Table 3). This data supports the conclusion that AQ inhibits the entry of toxins into the cytoplasm from acidified endosomes.
The discovery and development of novel drugs against biological threat agents such as Bacillus anthracis and Ebola virus, is an important concern worldwide. We have shown that AQ is a broad-spectrum drug that could be applied rapidly to cure biological emergencies caused by the several identified pathogens (Fig. 5). For example, the current Ebola crisis has already killed more than 10,000 people in 2014 and 2015. Repurposing of a compound with well-established safety and pharmacokinetic profiles—as well as proven high-volume GMP manufacturing—may be the only way that a therapy can be tested and deployed in time to protect the 21 + million people in the three hardest-hit West African countries.
To help address this Ebola crisis, as we were preparing this manuscript, we communicated our discoveries to Médecins Sans Frontières (MSF, Doctors Without Borders), and encouraged them to explore whether the administration of AQ in West African countries hit by Ebola epidemic is associated with a reduced mortality due to Ebola infections. MSF conducted a study and observed that the administration of AQ provided a substantial protection against Ebola mortality and reduced the mortality risk by 31%, and in this study MSF acknowledged the authors of this study (https://www.youtube.com/watch?v=rTyoc4s1Mco).
As seen in current Ebola epidemic, the human host can be co-exposed to numerous deadly pathogens and thus the infected individual will need to take numerous countermeasures (each with their own side-effects) to protect against multiple infectious organisms. Therefore, therapies capable of inhibiting multiple pathogens are needed. Broad-spectrum anti-pathogen drugs, capable of simultaneously inhibiting numerous unrelated pathogens, could be developed by targeting host proteins commonly exploited by those pathogens. In this work we show that AQ inhibits the host target rather than the pathogen, which makes AQ host-oriented broad-spectrum antimicrobial that is less likely to be circumvented by pathogen mutations that lead to microbial resistance to the countermeasure.
AQ was discovered by Parke-Davis in the 1940s and was approved by the FDA as an anti-malarial in the late 1940s and early 1950s under the trade name Camoquine. AQ is currently on the WHO’s Model List of Essential Medicines. Today AQ is recommended as a frontline anti-malarial therapy in combination with artemisinin. AQ belongs to the “quinoline antimalarials” (Reviewed in42). AQ inhibits Plasmodium falciparum phosphoethanolamine methyltransferase, an enzyme found in malarial parasites but not in humans43. Here we report that AQ also binds and blocks the function of host cathepsin B protein and thus entry of key pathogens into the cytoplasm.
Since AQ has been used for the past 60 years, its safety and pharmacokinetic profiles are well known. For example, it has been determined that after oral administration in healthy subjects, AQ is quickly absorbed and biotransformed into its main active form, DEAQ, which in turn is slowly eliminated with a terminal half-life of 9–18 days. The availability of PK values for AQ allows us to compare it to our in vitro data. The EC50 values for all of the tested pathogens inhibited by AQ or by DEAQ were at low μM range. Importantly, the known Cmax values (maximal amounts of drug in the blood after oral administration) of DEAQ in humans are in low μM range43,44,45 and are comparable to the DEAQ EC50 values found in vitro for tested pathogens. This suggests that it is possible to achieve anti-pathogen effective AQ doses in blood by orally administered AQ.
Chemicals and Reagents
All toxins were purchased from List Biological Laboratories. FP59 was a kind gift from S. Leppla (National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, MD). An FDA-approved drug library comprising of 1,581 drugs was purchased from Johns Hopkins, titled, Johns Hopkins Clinical Compound Library (JHCCL) version 1.0. The drugs arrived as 10 mM stock solutions in sealed microtiter plates and were made using DMSO or water as solvents. Drugs were arrayed in 96-well plates and screened at a stock concentration of 10 mM. The library was stored at −20 °C until use. Prior to use, the library of drugs was thawed at 25 °C. Compounds that were determined to be compounds of interest, were isolated and reproduced from 10 mM solutions. Amodiaquine, Chloroquine, Cinchonine, Primaquine, and Quinidine were purchased from Sigma-Aldrich (St. Louis, MO, USA). All drugs were prepared at 10 mM using DMSO as a solvent. Desethyl-amodiaquine and desethyl-chloroquine were purchased from Toronto Research Chemicals Inc. Anti–N-terminal MEK-2, anti-tubulin, and anti-PA antibodies were purchased from Santa Cruz Biotechnology. Purified human cathepsin B protein used for NMR experiments was purchased from ACROBiosystems.
Cellular Drug Screens
RAW264.7-pGIPZ(−)2 mouse macrophage cells were maintained in DMEM (Sigma-Aldrich) supplemented with 10% FBS (Bioexpress) and 100 μg/mL penicillin and 100 μg/mL streptomycin. RAW264.7-pGIPZ(−) cells (10,000 per well) were seeded in 96-well plates (100 μl/well) 24 hours before the assay. During the drug library screen assay, 0.75 μl of 3.3 mM drugs were added to 150 μl of cell-containing media to achieve 16 μM of each compound per well. Cells were treated with compounds for 1 hour at 37 °C 5%CO2, and then challenged with anthrax toxins, such that the final toxins concentrations were 0.5 μg/ml. Cells were treated with toxin and drugs for 6 hours. As rodent cells are resistant to diphtheria toxin, C32 human melanoma cell line was used for diphtheria toxin screening, where cells were treated with 2 μg/ml for 24 hours. Determination of cell viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed as described46. Cell viability is shown as the percentage of surviving cells obtained relative to cells treated with DMSO (100%).
FRET MAPKKide LF activity
For drug testing in 96-well plates, the reaction volume was 250 μl per well, containing 20 mM HEPES pH 7.2, 5 μM MAPKKide conjugated with DABYL and FITC (List Biological Laboratories, Inc), and 3.3 μM of JHCCL compound. The reaction was initiated by adding LF to a final concentration of 6 μg/ml. Kinetic measurements were obtained at 37 ºC every 40 sec for 40 min using a fluorescent plate reader. Excitation and emission wavelengths were 490 nm and 523 nm, respectively, with a cutoff wavelength of 495 nm.
Cells were seeded in a 96-well plate at a density of 10,000 cells/well 1 d before toxin treatment. Various concentrations of LF or FP59 combined with a fixed concentration of PA (500 ng/mL) were added to the wells, and cells were incubated for 6 h at 37 °C. Cell viability was measured by MTT assay. In other toxin treatment experiments, cells were pre-treated with various concentrations of drugs, and then treated with constant concentrations of 8.3 μg/ml of C. difficile toxin B, 500 ng/ml of P. aeruginosa Exotoxin A, or 500 ng/ml of Cholera toxin for 6 hours. RAW264.7 survival was measured by MTT assay. Each data point shown for MTT assays indicates the mean ± SD value obtained in triplicate assays done in a representative experiment. At least three such experiments were routinely carried out.
MEK Cleavage Assay
RAW264.7 cells were pre-treated with 66.67 mM of AQ for 1 hour. Following the pre-treatment, the cells exposed to 1 mg/mL of PA and LF at 37 °C for up to two hours in the presence of 16.67 μM of AQ. The cells were then washed with cold PBS for 5× and lysed with RIPA buffer containing a protease inhibitor mixture (Roche). Cell lysates were quantified using the BCA protein quantification kit (Pierce) and loaded onto 4–12% denaturing gels (Criterion XT Precast Gel, Bio-Rad). After electrophoresis for several hours, the gel was transferred overnight to nitrocellulose membranes; membranes were probed with anti-MEK-2 or anti tubulin antibodies. Quantitative Western blot analyses of the bands were accomplished using the VersaDoc 1000 instrument (Bio-Rad) or Odyssey infrared imaging system (LI-COR Biosciences).
Biochemical Assay of PA Binding and Internalization
Cells were pre-treated with AQ as described above for 1 h, either at 4 °C for PA binding or at 37 °C for PA internalization assays cells were exposed to 1 μg/mL of PA at 4 °C for 1 h for binding assay or at 37 °C for 1 h for internalization assay. Cells were then washed with PBS solution three times and lysed in RIPA buffer containing a protease inhibitor mixture (Roche). Western blot analysis was performed using anti-PA antibody anti-tubulin monoclonal antibody (Sigma-Aldrich). Chemiluminescence of bands and their relative intensities were revealed using a VersaDoc 1000 instrument (Bio-Rad).
Caspase-1 Activity Assay
Cells were treated with AQ for 1 h before addition of 500 ng/ml LF-PA for an additional 2 h. FAM FLICA™ Caspase 1 Assay Kit was obtained from ImmunoChemistry Technologies LLC. FLICA reagent was added for 1 h. FLICA fluorescence was visualized as follows: cells were washed three times in PBS, fixed in 4% (wt/vol) paraformaldehyde, and examined under a fluorescence microscope (DM5500 B; Leica).
Staining Cells with Lysosensor Green DND-189
Cells were treated with AQ for 1 h before an addition of 500 ng/ml PA for an additional hour and then stained with Lysosensor Green DND-189 for 10 min at 37 °C. Cells were then washed and fluorescence was visualized as follows: cells were fixed in 4% (wt/vol) paraformaldehyde, and examined under a fluorescence microscope (DM5500 B; Leica).
Cathepsin B Activity Assay
Cathepsin B activity in total cell lysates was determined using an InnoZyme ™ cathepsin B activity assay kit (EMD Milipore) and performed according to the manufacturer’s instruction. Cathepsin B activity in cellular lysates was tested in the following way: RAW264.7 cells untreated with drugs were lysed, and equal amount of cathepsin B containing protein lysate was added to the substrate solution (EMD Milipore) with and without AQ, CQ, DEAQ, or DECQ at concentrations of 4, 8, 16, 33, or 66 μM. Cellular cathepsin B activity with and without drugs was tested by pre-treating cells with drugs for 1 hour, followed by lysing cells and testing cathepsin B activity with a fluorescently labeled substrate. The activity of 0.5 ng/μl of purified human cathepsin B was mixed with and without drugs without pre-incubation and detected with a fluorescently labeled substrate. Fluorescence intensity indicating cathepsin B activity was measured at an excitation wavelength of 370 nm and emission wavelength of 450 nm (Molecular Devices, Spectra Max 384 PLUS).
Rat intoxication challenge
The rat studies were performed at Explora Biolabs, San Diego, CA following Institutional Animal Care and Use Committee (IACUC) approved protocols. Five Male Sprague-Dawley rats (226 to 250 g; Charles River) per group were used. The toxin mixture was prepared for each group by mixing 12 μg of LF with 40 μg of PA or with 1.5, 3.0, or 6.0 mg/kg of Amodiaquine in a 500-μl volume per rat. Rats were monitored for signs of clinical illness or death for 14 days after the challenge.
All STD experiments were performed at 25 °C using a Bruker Avance 500-MHz spectrometer equipped with a cryogenic probe. The pulse scheme employed excitation sculpting with gradients, and a 50 ms spin lock filter (T1ρ) to suppress signals originating from the water and protein signals, respectively25. An irradiation power of 26 Hz was applied on-resonance at 0.04 ppm, and off-resonance at 30 ppm, for a total saturation time of 4 s. Spectra were collected in an interleaved manner to account for any temporal fluctuations. Separate control experiments were performed using samples of cathepsin B or Amodiaquine to confirm the selectivity of saturation. STD spectra were acquired with 4096 scans and 32 k data points using a spectral width of 7002.8 Hz centered at 2352 Hz. All experiments were performed in deuterated tris buffer: 50 mM D11-Tris, 150 mM NaCl, pH 7.5 supplemented with 8% D2O. The sample used for STD measurements contained 20 mM and 2 mM cathepsin B and Amodiaquine, respectively. The STD NMR data were processed and analyzed using Topspin 3.1 software (Bruker, Billerica Ma). STD effects were calculated according to the formula: ASTD = (I0 − Isat)/I0, where Isat and I0 are the intensity of the Amodiaquine signal recorded with and without saturation of the protein, respectively.
The procedures of all viral experiments are described in supplemental materials and methods. Specifically, infection of HeLa cells with Ebola was done using Ebola virus (Kikwit) MOI = 0.5 (calculated for 4,000 cells/well, assuming one complete round of replication of HeLa cells at 15 ± 2 hrs after cell seeding). Cells were incubated with the virus for 24 or 48 h. Infection was terminated by fixing samples in formalin solution, and immuno-staining was used to visualize infected cells. Cells were treated with anti-GP specific monoclonal antibody (6D8) (1 to 1000 dilution) followed by anti-mouse IgG conjugated with Dylight488 (Thermo) (1 to 1000 dilution) in blocking buffer containing 3% BSA in PBS. Nuclei were stained with Draq5 (Biostatus) diluted in PBS buffer. Images were acquired on the Opera imaging instrument (Perkin Elmer) using 10× Air objective and four images/well were acquired and analyzed using PE Acapella algorithms.
How to cite this article: Zilbermintz, L. et al. Identification of agents effective against multiple toxins and viruses by host-oriented cell targeting. Sci. Rep. 5, 13476; doi: 10.1038/srep13476 (2015).
We thank Dr. Stephen Leppla of the NIAID for a kind gift of FP59 toxin and Dr. Robert Peterson for assistance with the NMR spectroscopy. We acknowledge the Ralph M. Parson’s Foundation award awarded to K.G.I. (PI Dr. Steven Casper). R.T.C. and M.S. acknowledge grant support from the National Institutes of Health (R01 AI52217 and F31GM101931, respectively).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/